A severe haematologic adverse reaction after high dosage radioiodine therapy following blood stem cell mobilization with growth factors

M. Freesmeyer

doi:10.1055/s-0037-1621656

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2011; 50(04): N34-N36
DOI: 10.1055/s-0037-1621656

Case report

Schattauer GmbH

A severe haematologic adverse reaction after high dosage radioiodine therapy following blood stem cell mobilization with growth factors

M. Freesmeyer

¹Nuclear Medicine, University Hospital Jena, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Dorn R, Kopp J, Vogt H. et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44: 451-456.
2 Durante C, Haddy N, Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899.
3 Elfenbein GJ, Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004; 32: 327-339.
4 Gunther HH, Schober O, Schwarzrock R, Hundeshagen H. Hematologic long-term modifications after radioiodine therapy in carcinoma of the thyroid gland. II. Modifications of the bone marrow including leucemia. Strahlenther Onkol 1987; 163: 475-485.
5 Isola LM, Scigliano E, Skerrett D. et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997; 20: 1033-1037.
6 Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973-981.
7 Lowenthal RM, Ragg SJ, Anderson J. et al. A randomized controlled clinical trial to determine the optimum duration of G-CSF priming prior to BM stem cell harvesting. Cytotherapy 2007; 9: 158-164.
8 MacHida U, Tojo A, Takahashi S. et al. The effect of granulocyte colony-stimulating factor administration in healthy donors before bone marrow harvesting. Br J Haematol 2000; 108: 747-753.
9 McNiece IK, Briddell RA. Stem cell factor. J Leukoc Biol 1995; 58: 14-22.
10 Petrich T, Widjaja A, Musholt TJ. et al. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 2001; 28: 203-208.